Superworth

Cadre CDRE

Medical - Instruments & Supplies, Healthcare
$31.51
+3.79%
Market cap
$1.3B
PE
38.9×
4y median 35.9×
Forward PE
n/m
not a meaningful number
Price to sales
2.0×
EV/EBIT
24.2×
Revenue, 12 months
$685.6M
+20% on a year ago
Net margin
5.3%
Free cash flow yield
5.8%

Cadre trades at 38.9× trailing earnings, pricier than 73% of the last ten years. Revenue was $685.6M over the last twelve months, up 20% on a year earlier with a 5% net margin.

Charts

Financials

Income statement for CDRE, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$125.1M+12%$124.6M+1%$137.9M+23%$144.3M+19%$109.4M−13%$176M+41%$130.1M−6%$157.1M+9%$155.9M+43%$167.2M−5%$155.4M+20%$207.1M+32%
Cost of revenue$71.5M+6%$74.8M−0%$80.2M+23%$85.7M+22%$69.4M−3%$98.8M+32%$74M−8%$92.9M+8%$89.2M+29%$94.6M−4%$95.3M+29%$120M+29%
Gross profit$53.6M+23%$49.8M+3%$57.6M+24%$58.6M+16%$40M−25%$77.2M+55%$56.1M−3%$64.2M+10%$66.6M+67%$72.6M−6%$60.2M+7%$87.1M+36%
SG&A$36.3M+14%$34.9M+1%$40.7M+16%$38.6M+13%$34M−6%$45M+29%$41.8M+3%$45.1M+17%$45.6M+34%$50.6M+12%$48.8M+17%$63.2M+40%
$16.7M+62%$12.7M−0%$12M+7%$20M+26%$5.4M−68%$29.4M+132%$13.6M+13%$14.7M−26%$18.7M+244%$20.4M−31%$7.5M−45%$22.5M+53%
Interest expense$1.1M−32%$804K−53%$1.6M−0%$2M+98%$2M+86%$2.2M+173%$2.2M+36%$3.6M+79%$3M+52%$3.6M+66%$4.3M+91%$5M+40%
Pre-tax income$15.3M+122%$12.4M−2%$8.9M−11%$17.6M+16%$5M−68%$22.7M+83%$12.6M+42%$17.2M−2%$14.8M+198%$17.7M−22%$2.8M−78%$16.9M−2%
$4.3M+119%$2.8M−54%$2M−33%$5M+19%$1.3M−69%$9.7M+245%$3.4M+71%$5M−1%$3.9M+192%$5.9M−39%$856K−75%$5.5M+10%
Net income$11.1M+124%$9.6M+45%$6.9M−1%$12.6M+14%$3.7M−67%$13M+35%$9.2M+34%$12.2M−3%$10.9M+199%$11.7M−10%$2M−79%$11.4M−7%
$0.29+123%$0.25+39%$0.18−5%$0.31+7%$0.09−69%$0.32+28%$0.23+28%$0.30−3%$0.27+200%$0.23−28%$0.05−78%$0.26−13%
37.9M+1%38.2M+2%38.6M+3%40.9M+8%40.9M+8%41M+7%41M+6%40.9M+0%41M+0%50.8M+24%43.4M+6%43.4M+6%

EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 5 periods, Q4 FY20 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Cadre's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
CDRECadre$1.3B38.9×35.9×2.0×+20%5.3%
EYENational Vision$1.4B28.1×52.7×0.7×+8%2.5%
STAAStaar Surgical$1.3B356×144×3.7×+51%1.1%
BVSBioventus$1.1B17.1×27.1×1.9×+4%9.4%
IARTIntegra Lifesciences$1.1B80.1×46.3×0.6×+1%0.8%
IRMDIradimed$1B42.5×41.5×11.4×+11%26.8%
LMATLemaitre Vascular$1.9B28.5×42.0×7.1×+12%25.0%
INSPInspire Medical Systems$1.9B14.5×56.6×2.2×−0%15.0%
UFPTUFP Technologies$2.2B30.6×25.6×3.5×+7%11.4%
MOVMovado$710.9M17.7×13.4×1.0×+5%6.0%
WRBYWarby Parker$2.9B341×359×3.2×+11%0.8%
Peer median$1.3B29.6×44.1×2.7×+8%7.7%

More on Cadre

Each number over time

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .